Beone Medicines Ltd. Class A · SSE:688235
Wang Lai sold 1,367 Beone Medicines Ltd. Class A shares (Form 4)
Traded Jun 8, 2026 · Filed Jun 10, 2026
On Jun 8, 2026, Wang Lai (President, Global Head of R&D) sold 1,367 Beone Medicines Ltd. Class A shares at an average US$269.38 for US$368K, leaving 0 shares. Filed Jun 10, 2026 (Form 4).
- Sold
- 1,367 shares
- Price
- US$269.38 average (US$269.34 to US$270.73)
- Value
- US$368K
- Holding after
- 0 shares
- Trading plan
- No
- Role
- President, Global Head of R&D
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Jun 8, 2026 | American Depositary Shares | Sale | 1,327 | US$269.34 | 40 | Direct |
| Jun 8, 2026 | American Depositary Shares | Sale | 40 | US$270.73 | 0 | Direct |
Source
Related
- Beone Medicines Ltd. Class A
- Wang Lai
- Beone Medicines Ltd. Class A shareholders
- Form 4 · Wang Lai · Jun 25, 2026
- Form 4 · Wang Lai · Jun 18, 2026
- Form 4 · Wang Lai · Jun 15, 2026
- Form 4 · Wang Xiaodong · Oct 15, 2026
- Form 4 · Lee Chan Henry · Oct 2, 2026
- Form 4 · Wang Xiaodong · Sep 30, 2026
- Form 4 · Baker Bros. Advisors LP · Sep 16, 2026
- Schedule 13D/A · Baker Bros. Advisors LP · Sep 16, 2026